Literature DB >> 1606772

Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis.

B F Murphy1, I McDonald, K F Fairley, P S Kincaid-Smith.   

Abstract

40 patients with idiopathic membranous glomerulonephritis were randomized to receive either no treatment or a regime of cyclophosphamide for 6 months, and warfarin and dipyridamole for two years. During the two years of the trial there was no significant deterioration in renal function in either group. A significantly greater improvement in urinary protein excretion was, however, observed at all time points in the treatment group. Plasma albumin was also significantly higher in the treatment group at 18 and 24 months. As progressive deterioration in renal function in membranous glomerulonephritis is associated with persistent heavy proteinuria these results suggest a beneficial effect of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606772

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  11 in total

Review 1.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 2.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 3.  Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Yizhi Chen; Arrigo Schieppati; Guangyan Cai; Xiangmei Chen; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Annalisa Perna
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

4.  Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis.

Authors:  R Brunkhorst; E Wrenger; K M Koch
Journal:  Clin Investig       Date:  1994-03

5.  Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis.

Authors:  T Tóth; S Takebayashi
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 6.  Idiopathic membranous nephropathy: management strategies.

Authors:  Marco Quaglia; Piero Stratta
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

7.  Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients.

Authors:  Hua-Zhang Qin; Lei Liu; Shao-Shan Liang; Jing-Song Shi; Chun-Xia Zheng; Qing Hou; Ying-Hui Lu; Wei-Bo Le
Journal:  BMC Nephrol       Date:  2017-01-05       Impact factor: 2.388

Review 8.  Unresolved issues and current concepts in management of primary glomerulonephritis.

Authors:  Suresh Chandra Dash; Fahd A Al-Muhanna
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

9.  Chapter 7: Idiopathic membranous nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06

10.  Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.

Authors:  Song Ren; Ying Wang; Li Xian; Tadashi Toyama; Meg Jardine; Guisen Li; Vlado Perkovic; Daqing Hong
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.